PRODUCT DETAILS VIEW ALL PRODUCTS

Allercet M Tablet (Montelukast + Levocetirizine)

  • Each uncoated bilayered tablet contains: Montelukast sodium IP equivalent to Montelukast 10 mg, Levocetirizine dihydrochloride IP 5 mg.
  • Indicated for treatment of allergic rhinitis in adults only.
  • Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.
  • Adults (>15 years): 1 tablet once daily.
  • Contraindicated in patients with known hypersensitivity to montelukast, levocetirizine, to other piperazine derivatives or to any of the excipients.
  • Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients taking montelukast. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor co-ordination such as operating machinery or driving a motor vehicle after ingestion of levocetirizine. . While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, montelukast should not be abruptly substituted for inhaled or oral corticosteroids.
  • There are no adequate and well-controlled studies in human pregnancy, lactation and children. This product should only be used in pregnancy if considered essential by the physician. Is not recommended for use in children below the age of 12 years.
  • Allercet-M may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. montelukast is a potent inhibitor of CYP 2C8. Hence caution to be exercised on administration of drugs metabolized by CYP 2C8.
  • Dyspepsia, abdominal pain, rash, dizziness, headache, fatigue, fever, trauma, cough, nasal congestion, somnolence, fatigue, dry mouth.
  • Anti-Allergics